Sissetulev kiriAvalik
Infopäring
Sotsiaalministeerium · 8. veebruar 2023
- Viit
- 1.5-1.1/660-1
- Registreeritud
- 8. veebruar 2023
- Dokumendi liik
- Sissetulev kiri
- Adressaat
- Citeline
- Saabumis/saatmisviis
- e-post
- Funktsioon
- 1.5 Asjaajamine. Info- ja kommunikatsioonitehnoloogia arendus ja haldus
- Sari
- 1.5-1.1 Teabenõuded, märgukirjad, selgitustaotlused
- Toimik
- 1.5-1.1/2023
- Vastutaja
- Mari Amos (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Terviseala asekantsleri vastutusvaldkond, Ravimiosakond)
- Lahendamise tähtaeg
- 10. märts 2023
Failid
Sisu (failidest)
Saatja: Grabenstein, Darcy <[email protected]>
Saadetud: 07.02.2023 18:23
Adressaat: <"SM Info">
Teema: Seeking information on clinical trial disclosure/results reporting - enforcement of
Estonia's penalties for noncompliance
Manused: image001.jpg
Hello – I am writing an article on global enforcement regarding the above topic, including Estonia’s
regulations and enforcement. Here are a few questions for your organization:
- What is the historical timeline for establishment of Estonia’s regulatory requirements, any penalties
and their enforcement?
- What are the guidelines? What, if any, are the penalties? Have they been enforced? If so, how?
- How do Estonia’s guidelines, penalties – and enforcement thereof – compare to that of other countries
in Europe?
Please respond by Friday.
Thank you
Darcy Grabenstein (she/her), APR, ABC
Senior Manager of Content Strategy | Citeline
Mobile: +1(215) 932-5476
[email protected]
www.pharmaintelligence.informa.com
Information Classification: General